GSK 3772847

Drug Profile

GSK 3772847

Alternative Names: CNTO 7160; GSK3772847

Latest Information Update: 04 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Research & Development
  • Class Antiasthmatics; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Interleukin 1 receptor-like 1 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma; Atopic dermatitis

Most Recent Events

  • 29 Jun 2017 GlaxoSmithKline plans a phase IIa trial for Asthma (Adjunctive treatment) (IV, Infusion) (NCT03207243)
  • 16 Mar 2017 Janssen completes a phase I trial in Asthma and Atopic dermatitis in Belgium and Germany (NCT02345928)
  • 27 Jul 2016 CNTO 7160 licensed to GlaxoSmithKline worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top